Biosimilars approved and marketed in Belgium

Biosimilars/General | Posted 18/05/2012 post-comment0 Post your comment

Last updated: 18 May 2012 

The Federal Agency for Medicines and Health Products (FAMHP), formerly the Directorate-General for Medicinal Products of the Federal Public Service (FPS) Public Health, created in January 2007, is the official authority for medicines and health products in Belgium and is also responsible for authorising biosimilars in Belgium [1]. This is carried out via the EU procedures (centralised, national, mutual recognition or decentralised) and following EMA guidelines for biosimilars.

picture 95

In view of their complexity, biosimilars are not considered interchangeable in Belgium. FAMHP recommends that biosimilars not be prescribed by INN (International Non-proprietary Name). If the prescriber decides to switch from one to the other (originator/biosimilar; biosimilar/originator or biosimilar/biosimilar), then this must be done with the necessary follow-up and the modification must be recorded accurately. Substitution of biosimilars by the pharmacist without consulting the doctor is not allowed in Belgium.

The first biosimilar, somatropin (Omnitrope), was approved for marketing in Belgium by FAMHP in April 2007. To date five biosimilars are approved for marketing in Belgium, see Table 1.

Table 1: Biosimilars approved and marketed in Belgium

Product name Generic name Therapeutic area Authorisation date Presentation Company
Binocrit epoetin alfa Chronic kidney failure
Anaemia
Cancer
14 Mar 2011 Solution for injection, prefilled syringe:
 1,000 IU/0.5 mL
10,000 IU/1.0 mL
2,000 IU/1.0 mL
20,000 IU/0.5 mL
3,000 IU/0.3 mL
30,000 IU/0.75 mL
4,000 IU/0.4 mL
40,000 IU/1.0 mL
5,000 IU/0.5 mL
6,000 IU/0.6 mL
8,000 IU/0.8 mL
Sandoz
Omnitrope somatropin Turner syndrome
Pituitary dwarfism
Prader-Willi syndrome

20 Apr 2007

19 Sept 2007

Solution for injection, 1.5 mL cartridge:
3.3 mg/mL 6.7 mg/mL
Sandoz
Retacrit epoetin zeta Anaemia
Chronic kidney failure
Autologous blood transfusion
Cancer
18 Dec 2007 Solution for injection, prefilled syringe:
10,000 IU/1 mL
1,000 IU/0.3 mL
20,000 IU/0.5 mL
2,000 IU/0.6 mL
30,000 IU/0.75 mL
3,000 IU/0.9 mL
40,000 IU/1.0 mL
4,000 IU/0.4 mL
5,000 IU/0.5 mL
6,000 IU/0.6 mL
8,000 IU/0.8 mL
Hospira
Tevagrastim filgrastim Neutropenia
Haematopoietic stem cell transplantation
Cancer
15 Sept 2008 Solution for injection/infusion, prefilled syringe:
30 mIU/0.5 mL
48 mIU/0.8 mL
48 mIU/0.5 mL
Teva
Zarzio filgrastim Neutropenia
Haematopoietic stem cell transplantation
Cancer
06 Feb 2009 Solution for injection/infusion, prefilled syringe:
30 mIU/0.5 mL
48 mIU/0.5 mL
Sandoz

IU: international units; mIU: milli-international units; mL: millilitre; mg: milligram
Source: FAMHP

Related article

Biosimilars approved in Europe

Source: FAMHP

comment icon Comments (0)
Post your comment
Related content
Biosimilars approved in Chile
ANAMED V21K19LT
Biosimilars/General Posted 19/11/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010